These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18846985)

  • 1. Should patients with type 2 diabetes focus on glycemic control to reduce their cardiovascular risk?
    Montori VM
    Pol Arch Med Wewn; 2008 Sep; 118(9):502-7. PubMed ID: 18846985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
    Christiansen AL; Madsbad S
    Ugeskr Laeger; 2002 Apr; 164(15):2022-4. PubMed ID: 11984999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical trial of the month. The STENO-2 study: a plea for global and intensive management of the type 2 diabetic patient].
    Scheen AJ; Estrella F
    Rev Med Liege; 2003 Feb; 58(2):109-11. PubMed ID: 12693313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid effects and cardiovascular disease risk associated with glucose-lowering medications.
    Stähli BE; Gebhard C; Tardif JC
    Curr Cardiol Rep; 2015 Jul; 17(7):608. PubMed ID: 26031672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic targets and cardiovascular disease.
    Cefalu WT
    N Engl J Med; 2008 Jun; 358(24):2633-5. PubMed ID: 18539919
    [No Abstract]   [Full Text] [Related]  

  • 6. [Metabolic control or reduction of vascular risk with current treatments. What is the priority?].
    Alonso Fernández M
    Semergen; 2018 Jun; 44 Suppl 1():26-32. PubMed ID: 30322470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tight glycemic control in the management of diabetic patients: what has changed since the '90s in the clinical approach?].
    Fiorentino TV; Sesti G
    G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):13S-20S. PubMed ID: 25623546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

  • 9. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
    Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
    Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 2 diabetes and HbA1c targets.
    Prescrire Int; 2008 Dec; 17(98):254. PubMed ID: 19425272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.
    Lamanna C; Monami M; Marchionni N; Mannucci E
    Diabetes Obes Metab; 2011 Mar; 13(3):221-8. PubMed ID: 21205121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Lamanna C; Gori F; Marchionni N
    Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):604-12. PubMed ID: 19427768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes medications and cardiovascular disease: at long last progress.
    Lupsa BC; Inzucchi SE
    Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):87-93. PubMed ID: 29369916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive glucose control in type 2 diabetes.
    Parashar A
    N Engl J Med; 2008 Oct; 359(14):1520; author reply 1520-1. PubMed ID: 18837128
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
    Panicker GK; Karnad DR; Salvi V; Kothari S
    J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association.
    Skyler JS; Bergenstal R; Bonow RO; Buse J; Deedwania P; Gale EA; Howard BV; Kirkman MS; Kosiborod M; Reaven P; Sherwin RS; ; ;
    J Am Coll Cardiol; 2009 Jan; 53(3):298-304. PubMed ID: 19147051
    [No Abstract]   [Full Text] [Related]  

  • 18. [Need of tight blood pressure control in type 2 diabetes. The intervention study ADVANCE gives clear information].
    Nilsson PM
    Lakartidningen; 2007 Oct 17-23; 104(42):3028-9. PubMed ID: 17985709
    [No Abstract]   [Full Text] [Related]  

  • 19. Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?
    Athyros VG; Mitsiou EK; Tziomalos K; Karagiannis A; Mikhailidis DP
    Curr Vasc Pharmacol; 2010 Jan; 8(1):1-4. PubMed ID: 20394107
    [No Abstract]   [Full Text] [Related]  

  • 20. [How does the PROactive Study change therapy of diabetes?].
    Erdmann E
    MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.